These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9103514)
41. Evidence for CYP2D1-mediated primary and secondary O-dealkylation of ethylmorphine and codeine in rat liver microsomes. Xu BQ; Aasmundstad TA; Christophersen AS; Mørland J; Bjørneboe A Biochem Pharmacol; 1997 Feb; 53(4):603-9. PubMed ID: 9105413 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. Butz RF; Jones EC; Welch RM; Findlay JW Drug Metab Dispos; 1983; 11(5):481-8. PubMed ID: 6138235 [TBL] [Abstract][Full Text] [Related]
43. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657 [TBL] [Abstract][Full Text] [Related]
44. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781 [TBL] [Abstract][Full Text] [Related]
45. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173 [TBL] [Abstract][Full Text] [Related]
46. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. Halling J; Weihe P; Brosen K Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597 [TBL] [Abstract][Full Text] [Related]
47. Codeine: Time to Say "No". Tobias JD; Green TP; Coté CJ; ; Pediatrics; 2016 Oct; 138(4):. PubMed ID: 27647717 [TBL] [Abstract][Full Text] [Related]
48. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Skarke C; Jarrar M; Erb K; Schmidt H; Geisslinger G; Lötsch J Clin Pharmacol Ther; 2003 Oct; 74(4):303-11. PubMed ID: 14534517 [TBL] [Abstract][Full Text] [Related]
49. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. Colizza K; Awad M; Kamel A Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832 [TBL] [Abstract][Full Text] [Related]
50. NTP Toxicology and Carcinogenesis Studies of Codeine (CAS No. 76-57-3) in F344 Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1996 Aug; 455():1-275. PubMed ID: 12587021 [TBL] [Abstract][Full Text] [Related]
51. Time-dependent codeine hypoalgesia and hyperalgesia in domestic fowl. Sufka KJ; Hughes RA Pharmacol Biochem Behav; 1992 Feb; 41(2):349-53. PubMed ID: 1574524 [TBL] [Abstract][Full Text] [Related]
52. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Sowinski KM; Burlew BS Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616 [TBL] [Abstract][Full Text] [Related]
53. Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. Somogyi A; Bochner F; Chen ZR Eur J Clin Pharmacol; 1991; 41(4):379-82. PubMed ID: 1804656 [TBL] [Abstract][Full Text] [Related]
54. Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. Xu BQ; Aasmundstad TA; Lillekjendlie B; Bjørneboe A; Christophersen AS; Mørland J Pharmacol Toxicol; 1997 Apr; 80(4):171-81. PubMed ID: 9140136 [TBL] [Abstract][Full Text] [Related]
55. The role of active metabolites in dihydrocodeine effects. Schmidt H; Vormfelde SV; Walchner-Bonjean M; Klinder K; Freudenthaler S; Gleiter CH; Gundert-Remy U; Skopp G; Aderjan R; Fuhr U Int J Clin Pharmacol Ther; 2003 Mar; 41(3):95-106. PubMed ID: 12665158 [TBL] [Abstract][Full Text] [Related]
56. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Chen ZR; Somogyi AA; Reynolds G; Bochner F Br J Clin Pharmacol; 1991 Apr; 31(4):381-90. PubMed ID: 2049245 [TBL] [Abstract][Full Text] [Related]
57. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Lam J; Woodall KL; Solbeck P; Ross CJ; Carleton BC; Hayden MR; Koren G; Madadi P Forensic Sci Int; 2014 Jun; 239():50-6. PubMed ID: 24747667 [TBL] [Abstract][Full Text] [Related]
58. Functional phenotyping of the CYP2D6 probe drug codeine in the horse. Gretler SR; Finno CJ; Kass PH; Knych HK BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736 [TBL] [Abstract][Full Text] [Related]
59. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Sindrup SH; Brøsen K; Bjerring P; Arendt-Nielsen L; Larsen U; Angelo HR; Gram LF Clin Pharmacol Ther; 1990 Dec; 48(6):686-93. PubMed ID: 2249379 [TBL] [Abstract][Full Text] [Related]